$695 | Single User
$2850 | Site License
$5650 | Global License

Commercialisation of Biosimilars: strategies for market penetration
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Nov 2013 | 76 | In Stock
Related Topics: Biosimilars , Medical , Pfizer

Introduction

Introduction


Times, they are a-changin’—at least for the American biological product market.



With five major biological products worth a collective US billion in annual sales now facing imminent patent expiration, the market is poised to develop and commericialise biosimilars. With the new abbreviated regulatory pathway now in place in the US, the race is on to develop strategies that will ensure the rapid acceptance of biosimilars.



And some of those approaches will come directly from the European experience. While their lessons have been slow in coming, the EU is ahead of the US in market development and currently leads the world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned.



In Commercialisation of Biosimilars: strategies for market penetration, FirstWord expertly examines the European experience and what it means for other developed markets. Based on expert opinions from the top commentators in the field, the report offers insight into how European biosimilar markets have evolved, includes up to the minute US case studies and which strategies have proven effective—and why.


Scope


Key Report Features of Commercialisation of Biosimilars: strategies for market penetration include:


  • Up to date analysis of the European model and commentary on why uptake varies by market

  • A look at which products are now in advanced development

  • Case studies contrasting the US experience of somatropin and enoxaparin

  • Strategies to improve market penetration

  • Puchase Reasons


    Key Benefits


    The biosimilar market in the US is poised to take advantage of major biologicals going off patent. Through Commercialisation of Biosimilars: strategies for market penetration, you will:


  • Understand the differences in the US experiences with somatropin and enoxaparin biosimilars

  • Gain insight from experts on potential issues regarding interchangeability, in both regulation and in practice

  • Gain knowledge of how to design strategies to influence key opinion leaders

  • Understand why biosimilar acceptance is slower than most new generic drugs

  • Commercialisation of Biosimilars: strategies for market penetration answers key questions:


  • How much cross over in practice will be seen between the European and American markets?

  • What specific strategies will work in kick starting the acceptance of biosimilars in the US?

  • What are the potential advantages and disadvantages of alternative US biosimilar approval pathways?

  • How can the industry best educate decision makers on biosimilars’ value, efficacy and safety?

  • What lessons can be gleaned from US experiences to date?

  • Highlights


    Key quotes


    “When it comes to long term treatments I think that doctors are more reluctant to use biosimilars because immunogenicity concerns have been highlighted by the biotechnology industry. They want to see more evidence on their long term safety.” Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway



    “In a market like the US, you really will need these dual strategies where you need to have a pretty well thought out market access strategy, working with payers, while the sales and marketing tactics, will look a little bit different from what we're used to with traditional innovative products. It's not differentiating on the product profile but it's really establishing biosimilarity.” Sophie Opdyke, VP Commercial Development, Pfizer Biosimilars



    “For a biosimilar to come in there and think they're only going to compete on price, I think it's going to be a challenge for them, to say the least. I think we got too used to the analogy of how generics work in the US now and we forget all the early days. It takes a lot of trust building in these early years (of product safety and efficacy), to get people to an understanding to use such products. That's important.” Virginia Acha, Director Regulatory Affairs, Amgen, UK


    Content Highlights



    As the nascent US biosimilars industry prepares to commercialise, lessons can be learned from the European experience. In this report, you will discover:


  • The importance of utilising different strategies to enhance market penetration

  • How development pathway options for drugs targeting multiple diseases will offer the best chance of comprehensive marketing approvals

  • The anticipated differences in uptake between biosimilar insulin and antibodies indicated for oncology
  • Table of Contents
    for Commercialisation of Biosimilars: strategies for market penetration

    • 1.EXECUTIVE SUMMARY

      2.INTRODUCTION

      2.1.OVERVIEW

      2.2.DEFINITIONS

      2.2.1.Biologics

      2.2.2.Biosimilars

      2.2.3.Extrapolation

      2.2.4.Interchangeability and automatic substitution

      2.3.THE REGULATORY BACKGROUND

      2.3.1.Europe

      2.3.2.US

      2.3.3.Key differences between the EU and US

      2.3.3.1.Europe

      2.3.3.2.US

      2.4.KEY MARKET OPPORTUNITIES

      2.4.1.Types of biologic product

      2.4.2.Top selling biologic products

      2.4.3.Oncology

      2.4.4.Rheumatology

      2.4.5.Dermatology

      2.4.6.Gastroenterology

      2.4.7.Haematology (excluding haematological malignancies)

      2.4.8.Diabetes

      2.4.9.Respiratory

      2.4.10.Rare diseases

      2.4.11.Identified biosimilars in development

      3.THE EUROPEAN MARKET

      3.1.INTRODUCTION

      3.2.CURRENT EXPERIENCE

      3.2.1.Human growth hormone (hGH)

      3.2.2.EPO

      3.2.3.Filgrastim

      3.2.3.Pending biosimilar launches

      3.2.3.1.Biosimilar infliximab

      3.2.3.2.Biosimilar FSH

      3.2.3.3.Biosimilar Insulin

      3.2.4.Commercialization strategies

      3.2.4.1.Pricing

      3.2.4.2.Influencing decision makers

      3.2.4.3.Interchangeability and substitution

      3.2.4.4.Relationships with payers

      3.2.4.5.Countering defensive strategies

      4.THE US MARKET

      4.1.OVERVIEW

      4.2.EXPERIENCE TO DATE

      4.2.1.Human growth hormone (hGH)

      4.2.2.M-Enoxaparin

      4.2.3.tbo-filgrastim

      4.3.APPROVAL STRATEGIES

      4.3.1.The ‘paper NDA’

      4.3.2.BLA or abbreviated BLA?

      4.3.2.1.EPO

      4.3.2.2.Filgrastim

      4.3.2.3.Insulin

      4.3.2.4.Anti-TNF products

      4.3.2.5.Other antibodies

      4.3.3.Interchangeability

      4.3.4.Countering defensive strategies

      4.4.COMMERCIALISATION STRATEGIES

      4.4.1.Pricing

      4.4.2.Payer focused strategies

      4.4.3.Relationships with key decision makers

      4.4.4.Targeting specific groups

      4.4.5.Branding issues

      4.4.6.Countering defensive strategies

      5.CONCLUSIONS

      6.ACKNOWLEDGEMENTS

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    76 |

    Number of Pages

    124

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Commercialisation of Biologics: Benchmarking leading players
    Commercialisation of Biologics: Benchmarking Leading PlayersIt’s clear that the rapidly growing biol...
    01 Oct 2017 by FirstWord Pharma USD $2,245 More Info
    Commercialisation of Biologics: Benchmarking leading players
    Commercialisation of Biologics: Benchmarking Leading PlayersIt’s clear that the rapidly growing biol...
    01 Oct 2017 by FirstWord Pharma USD $2,245 More Info
    Orphan Drug Commercialisation and Market Access in Emerging Markets
    IntroductionMarket access for orphan drugs: Can your company break through in emerging markets?Find ...
    01 Jul 2016 by FirstWord Pharma USD $695 More Info
    Orphan Drug Commercialisation and Market Access in Emerging Markets
    Market access for orphan drugs: Can your company break through in emerging markets?Find out which em...
    01 Jun 2016 by FirstWord Pharma USD $2,195 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Commercialisation of Biosimilars: strategies for market penetration | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...